Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry. (April 2013)

• Record Type: Journal Article
• Authors: de Llano, Luis Pérez; Vennera, María del Carmen; Álvarez, Francisco J.; Medina, Juan F; Borderías, Luis; Pellicer, Concha; González, Héctor; Gullón, José A; Martínez-Moragón, Eva; Sabadell, Carlos; Zamarro, Soledad; Picado, César
• Is Part Of: Journal of asthma. Volume 50:Number 3(2013)
• Page Start: 296
• Page End: 301
• Publication Date: 2013-04
• Subjects: Asthma -- Periodicals; 616.238005
• DOI: 10.3109/02770903.2012.757780
• Languages: English
• ISSNs: 0277-0903

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <italic>Aim.</italic> To evaluate the effectiveness of omalizumab in non-atopic asthma. <italic>Methods.</italic> Using data from a multicenter registry of severe asthma, we evaluated and compared the clinical outcome of 29 omalizumab-treated severe non-atopic asthmatics with 266 omalizumab-treated severe allergic asthmatics. Effectiveness was assessed by considering severe exacerbations, pulmonary function, the Global Evaluation of Treatment Effectiveness (GETE) scale, and Asthma Control Test (ACT). <italic>Results.</italic> Omalizumab demonstrated significant improvement in the clinical status of non-atopic asthmatics as measured by GETE, which rose from 1.6 ± 1.1 to 2.8 ± 0.8 at 4 months (<italic>p</italic> = .0215) to 2.9 ± 0.9 at 1 year (<italic>p</italic> = .0093) and to 3.4 ± 0.6 at 2 years (<italic>p</italic> = .0078), and by the ACT, which increased from 13.0 ± 5.5 to 17.5 ± 5.4 at 4 months (<italic>p</italic> = .0236) to 17.9 ± 4.8 at 1 year (<italic>p</italic> = .0136) and to 20.6 ± 3.9 at 2 years (<italic>p</italic> = .0024). Forced expiratory volume in 1 second (FEV<sub>1</sub>) improved from 61.0 ± 19.4% to 65.1 ± 17.2 at 4 months to 64.1 ± 24.7 at 1 year and to 67.3 ± 23.0 at 2 years, but without significant differences between initial and follow-up measurements (<italic>p</italic> = .52, .91, and .45, respectively) and exacerbations decreased from 3.1 ± 3.5 to 1.9 ± 2.8 at 1 year (<italic>p</italic> = .1709) to 1.8 ± 4.4 at 2 years (<italic>p</italic> = .2344). The results were not significantly different from those obtained in atopic asthmatics. <italic>Conclusion.</italic> Anti-IgE therapy can be effective in non-atopic severe asthma.</p> </abstract>